Skip to main content
Wendy Introne, MD, Medical Genetics, Bethesda, MD

Wendy Jewell Introne MD

Medical Genetics•Bethesda, MD

Clinical Biochemical Genetics, Clinical Genetics

Physician

Join to View Full Profile

  • 10 Center DrBuilding 10 Crc, Room 3-2541Bethesda, MD 20892

  • Phone+1 301-451-8879

  • Fax+1 301-496-7157

Dr. Introne is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Introne's Full ProfileAlready have an account?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterResidency, Medical Genetics and Genomics, 1998 - 2001
  • Children's National Hospital
    Children's National HospitalResidency, Pediatrics, 1995 - 1998
  • University of New Mexico School of Medicine
    University of New Mexico School of MedicineClass of 1995

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 1996 - 2027
  • Clinical Biochemical Genetics
    American Board of Medical Genetics and Genomics Clinical Biochemical Genetics
  • Pediatrics
    American Board of Pediatrics Pediatrics
  • Clinical Genetics and Genomics
    American Board of Medical Genetics and Genomics Clinical Genetics and Genomics

Awards, Honors, & Recognition

  • Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Severe Bleeding with Subclinical Oculocutaneous Albinism in a Patient with a Novel HPS6 Missense Variant  
    William A Gahl, Dong Chen, Koyamangalath Krishnan, Wendy J Introne, American Journal of Medical Genetics Part A

Lectures

  • Novel Hermanksky-Pudlak Syndrome Type 6 Missense Variant Associated with Subclinical Oculocutaneous Albinism and Mild BleedingClinically Relevant Abstract 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Cycle Pharmaceuticals’ HARLIKU™ (Nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU)
    Cycle Pharmaceuticals’ HARLIKU™ (Nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU)June 19th, 2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Wendy Introne, Dr. Wendy Introne, MD, Dr. W Introne, Dr. Wendy Jewell Introne